Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 648.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,730 shares of the medical research company's stock after purchasing an additional 4,964 shares during the period. Captrust Financial Advisors' holdings in Bio-Rad Laboratories were worth $1,882,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BIO. Venturi Wealth Management LLC raised its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after buying an additional 87 shares during the last quarter. GeoWealth Management LLC increased its position in shares of Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after acquiring an additional 72 shares during the period. Picton Mahoney Asset Management grew its stake in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc acquired a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at about $33,000. Finally, UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

Shares of BIO traded up $5.26 during trading hours on Friday, hitting $248.45. The stock had a trading volume of 254,950 shares, compared to its average volume of 321,515. The firm has a 50-day moving average price of $243.51 and a 200 day moving average price of $299.31. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The firm has a market capitalization of $6.96 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's revenue for the quarter was down 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.30 EPS. As a group, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BIO shares. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Citigroup reduced their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Royal Bank of Canada lowered their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.